JUNS (Jupiter Neurosciences) Beginning Cash Position: $3.79 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Jupiter Neurosciences Beginning Cash Position?

Jupiter Neurosciences JUNS -5.26% Beginning Cash Position is $3.79 Mil as of Mar. 2026. The stock has 5 warning signs investors should review.

Jupiter Neurosciences's Beginning Cash Position for the quarter that ended in Mar. 2026 was $3.79 Mil.

Jupiter Neurosciences's quarterly Beginning Cash Position increased from Sep. 2025 ($1.88 Mil) to Dec. 2025 ($6.16 Mil) but then declined from Dec. 2025 ($6.16 Mil) to Mar. 2026 ($3.79 Mil).

Jupiter Neurosciences's annual Beginning Cash Position declined from Dec. 2023 ($0.06 Mil) to Dec. 2024 ($0.03 Mil) but then increased from Dec. 2024 ($0.03 Mil) to Dec. 2025 ($3.77 Mil).

Jupiter Neurosciences Beginning Cash Position Related Terms

Jupiter Neurosciences Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Jupiter Neurosciences's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Jupiter Neurosciences Beginning Cash Position Chart

Jupiter Neurosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 0.21 0.33 0.06 0.03 3.77

Jupiter Neurosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.77 2.71 1.88 6.16 3.79

Jupiter Neurosciences Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $3.79 Mil mean?
Jupiter Neurosciences (JUNS) has a Beginning Cash Position of $3.79 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Jupiter Neurosciences and its competitors.
Is Jupiter Neurosciences' Beginning Cash Position too high?
Jupiter Neurosciences' current Beginning Cash Position is $3.79 Mil.
How does Jupiter Neurosciences' Beginning Cash Position compare to CLGN and RNAZ?
Jupiter Neurosciences' Beginning Cash Position of $3.79 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Biotechnology company?
A good Beginning Cash Position depends on the Biotechnology industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Jupiter Neurosciences and its competitors. Jupiter Neurosciences's current Beginning Cash Position is $3.79 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jupiter Neurosciences stock overvalued right now?
Jupiter Neurosciences (JUNS) has a current Beginning Cash Position of $3.79 Mil. The current Beginning Cash Position is $3.79 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Jupiter Neurosciences (JUNS), the current Beginning Cash Position is $3.79 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Jupiter Neurosciences Business Description

Address 1001 North US Highway 1, Suite 504, Jupiter, FL, USA, 33477
Jupiter Neurosciences Inc is a clinical-stage research and development company focused on developing treatments for neuroinflammation through the resveratrol platform. Its platform product, JOTROL, is an enhanced oral formulation of resveratrol, which has many potential indications. In the larger disease areas, which are targeting Parkinson's Disease. The group is presently in the process of conducting a Phase IIa clinical trial in Parkinson's Disease. The company operates through two reportable segments: premium nutritional supplements and pharmaceutical operations focused on drug candidates for CNS and rare orphan diseases. It generates the majority of its revenue from Premium Nutritional Supplements, which includes commercialization and sales of the Company's Nugevia product line.